| Identification | Back Directory | [Name]
PLB-1001 | [CAS]
1440964-89-5 | [Synonyms]
CBT-101
BOZITINIB
PLB-1001
BOZITINIB (PLB-1001)
1,2,4-Triazolo[4,3-b]pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-[difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl]- | [Molecular Formula]
C20H15F3N8 | [MOL File]
1440964-89-5.mol | [Molecular Weight]
424.38 |
| Chemical Properties | Back Directory | [density ]
1.68±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 50 mg/mL (117.82 mM) | [form ]
Solid | [pka]
0.15±0.12(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1]. | [References]
[1] Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18. DOI:10.1016/j.cell.2018.09.038 |
|
|